US FDA’s Califf Acknowledges There Is ‘Price To Pay’ For Missed Inspections
Executive Summary
Commissioner Califf is questioned about the backlog of inspections and fact FDA staff are continuing to work remotely at Senate HELP Committee hearing. Senator Burr promises to be a roadblock to emergency COVID-19 funding.
You may also be interested in...
Peter Marks On How He Wants To Prepare For The Next Pandemic
Acknowledging the toll that vaccine opponents have taken on FDA operations, the CBER director emphasizes the need to create stand-by manufacturing capacity, conduct faster studies in special populations, and better understand the mRNA platform.
Moderna, Pfizer Nab Unanimous Votes For Pediatric COVID Vaccines But Advisors Hint At Moderna Dosing Advantage
US FDA advisory committee members raised some concerns regarding Pfizer’s three-dose schedule for children under five, suggesting Moderna’s two-dose primary series may be preferred.
US FDA May Rethink White Oak Campus As Agency Plots ‘New Normal’ For Work
A pilot project on the future of work at the FDA could lead to reduced office space requirements and improve recruitment and retention, officials say.